This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Jaypirca (pirtobrutinib)
General Description:
Jaypirca (pirtobrutinib) is a Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma (MCL) in adults. It works by selectively blocking the BTK enzyme, which is essential for the growth and survival of malignant B cells, helping to control cancer progression in patients whose disease has relapsed or is refractory to other treatments.
Jaypirca was approved by the U.S. Food and Drug Administration (FDA) in January 2023 for use in the United States.
Disease Indications:
Lymphoma (Mantle Cell Lymphoma – MCL)
Manufacturer:
Lilly
Usage:
Oral
Medicine Approved by:
• Food and Drug Administration (FDA)
Package:
• 1 bottle with 30 tablets × 50 mg
• 1 bottle with 56 tablets × 100 mg
Shipping:
Room Temperature Shipping
For this medication, standard shipping applies. This means that a consistent room temperature of 15°C to 25°C is maintained during transit.
How to Access Jaypirca (pirtobrutinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Jaypirca (pirtobrutinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
